South Korea Drug Delivery Systems Market

South Korea Drug Delivery Systems Market Size & Forecast:

• South Korea Drug Delivery Systems Market Size 2025: USD 5.47 Billion
• South Korea Drug Delivery Systems Market Size 2033: USD 10.31 Billion
• South Korea Drug Delivery Systems Market CAGR: 11.60%
• South Korea Drug Delivery Systems Market Segments: By Route (Oral, Injectable, Transdermal, Pulmonary, Others); By Technology (Controlled Release, Targeted Delivery, Smart Delivery, Others); By End User (Hospitals, Clinics, Homecare, Others) 

South Korea Drug Delivery Systems Market Summary

The South Korea Drug Delivery Systems Market was valued at USD 5.47 Billion in 2025. It is forecast to reach USD 10.31 Billion by 2033. That is a CAGR of 8.31% over the period.

South Korea's drug delivery systems play a role in how hospitals and pharmaceutical companies deliver drugs with more accuracy, while maintaining higher precision at targeted tissues and enhancing compliance at oncology, diabetes, and long-term chronic care, for instance. In the last 5 years, structural transition from conventional oral dominance to biologics-compatible, device-enabled delivery platforms has been happening, largely backed by quick uptake of injectable biologics, pre-filled syringes, and auto-injectors as drug developers create drug products requiring controlled/sustained release. Covid-19 pandemic played a role in stimulating investment in mRNA vaccines and cold-chain logistics, alongside prompt approval of innovative injectables from regulatory authorities. This, consequently, leads to prioritized delivery-oriented innovation on pharmaceutical companies' side, and a proliferation of outpatient and home-based drug delivery systems on hospital's side, which thus demands more sophisticated high-precision, patient-centric drug delivery systems.

Key Market Insights

• Seoul-Gyeonggi holds nearly 45% share of South Korea Drug Delivery Systems Market owing to extensive hospital & biotech infrastructure.
• Southeast industrial zone registers fastest growth, backed by escalating pharmaceutical manufacturing and clinical trial activities (2024-2030).
• Injectable drug delivery systems holds over 40% share, backed by biologics and in-hospital treatment regimens.
• Transdermal drug delivery systems stands for second major share owing to the augmented patient compliance in the treatment of chronic diseases.
• Smart drug delivery devices is the fastest growing segment through 2030, owing to rise in the utilization of connected health care.
• Oncology held nearly 30% share in the applications segments due to higher use of biologics and in-demand targeted treatment strategies.
• Diabetes management stands as fastest growing segment through 2030 owing to the increasing prevalent rate of chronic disease and development of innovative insulin delivery system.
• Hospitals hold 55% share in the end-user segments, owing to requirement of acute and specialized treatment.
• Home healthcare registers fastest growing end-user segments owing to outpatient treatment regimens and self-administration technology.

What are the Key Drivers, Restraints, and Opportunities in the South Korea Drug Delivery Systems Market?

Rising development of biological and targeted drugs with advanced drug delivery requirements (e.g., auto-injectors, infusion pumps, sustained-release drugs) in South Korea fuels the growth of South Korea Drug Delivery Systems Market. Increased focus on developing injectable and controlled-release based therapies due to moving drug pipelines in oncology and immunology away from oral dosage forms acts as a catalyst for the change in drug delivery systems development. Pharmaceutical companies are aiming for complex molecules with low bio-availability, where innovative drug delivery devices and formulations lead to improved treatment outcomes and higher product price, ultimately increasing sales and revenues for the device and formulation developers.

High regulatory and validation hurdles for combination drug-device products present an important restraint for the market. A synchronized regulatory approval route for drug and medical device components for these combination drug-device products results in a protracted commercialization timeline. The complex nature of these combination drug-device products enhances product development cost and delay in the time-to-market which affects the revenue potential in the short-term. Domestic manufacturers of small-to-medium sized products have lacked global regulatory experience and expertise for such combination products.

The growing trend in home-based and decentralized care models with use of smart drug delivery systems represents a significant growth opportunity for the South Korea Drug Delivery Systems Market. South Korea's advanced digital health network infrastructure is well suited for developing smart injectors with remote monitoring technology or connected infusion systems that can facilitate this shift in patient care settings. As more and more hospitals outsource the treatment of chronic conditions outside clinical sites, growing need for easy-to-use and self-administrated drug delivery systems are created that offers long-term scalability for digital therapeutics-enabled delivery solutions.

What Has the Impact of Artificial Intelligence Been on the South Korea Drug Delivery Systems Market?

AI is a driving force for change in the South Korea Drug Delivery Systems Market, allowing for increased accuracy in dosage administration and improved intelligence within the delivery devices, as well as providing optimization in pharmaceutical manufacturing processes. Within connected infusion pumps and smart injectors, AI-based algorithms process patient response data to adjust dose rates in real-time. This provides enhanced therapy accuracy, particularly for chronic disease and oncology applications. Furthermore, ML algorithms are being developed to allow for optimization of drug release profiles and prediction of patient compliance, further enabling device manufacturers to design smarter delivery systems.

Operationally, AI improves manufacturing efficiency through the ability to detect formulation variability and optimize fill-finish operations. This contributes to a decreased rate of batch failures and an increase in overall yield consistency. Additionally, hospitals utilizing AI-based delivery platforms report enhanced patient compliance monitoring and less manual administration of dosage scheduling. This contributes to improved workflow efficiency and a decrease in operational costs.

A structural impediment to widespread adoption is the lack of sufficient high-quality clinical data required for training AI algorithms to respond effectively across a diverse array of patient populations. The costs of integration of AI-powered delivery devices are substantial and this presents a significant barrier to implementation for mid-size device manufacturers. The regulatory process of validation for AI-based adjustments to dosages has not yet fully materialized to ensure commercial viability on a widespread scale.

Key Market Trends

• During the period of 2019-2025, dominance shifting from oral dosages to injectable biologic treatments spurred the demand of auto-injectors throughout South Korea tertiary hospitals.
• During the COVID-19 pandemic, accelerated innovation of mRNA and vaccine delivery stimulated regulators to grant expedited approval to advanced injectable devices starting from 2020 onwards.
• The development and adoption of Bluetooth tracking smart injectors rose steadily from 2021-2026, marking a transition of patient adherence monitoring from manually recording to digital tracking.
• MFDS in South Korea streamlined combined product approval paths from post-2022, but compliance time and quality standards of devices-pharmaceutical combinations were also improved.
• Since 2020, the increasing preference of home healthcare systems shifted chronic disease management toward home self-administration delivery systems via the outpatient channel.
• Post-2021 supply chain interruptions increased domestic production needs for delivery devices and reduced dependence on raw material imported from the United States and Europe.
• Global leading companies Medtronic and Johnson & Johnson extended partnerships with Korean companies from 2022 to co-develop tailored drug delivery platforms in South Korea.
• Starting from 2023, the application of AI-empowered drug delivery systems to high-risk cancer treatment provided enhanced dosage accuracy and hospital administration efficiency.
• Increasing market share of biosimil from 2021 onwards placed manufacturers under intense price competition, thus forcing development of innovative delivery differentiation strategies.

South Korea Drug Delivery Systems Market Segmentation

By Route : 

The use of injectable systems is expected to expand as the use of biologics increases throughout South Korean healthcare institutions. Oral routes of administration will decline as precision therapies become dominant, where tight control of dosing is required and rapid onsets of treatment are critical. Hospitals have a clear preference for injection based delivery for chronic conditions and oncology care.

Transdermal and pulmonary systems are being adopted incrementally as they offer convenience to the patient, and decrease patient dependence on hospital administration. Home care models enable non-invasive delivery systems to be used on a broader scale and extend the use to settings beyond the clinic. Oral systems will still play a role for basic care; however more complex treatment regimens will continue to move toward injected based therapy with device administered delivery systems.

By Technology : 

Controlled Release systems will continue to see robust use due to the advantages of constant dosing for long-term therapy of chronic diseases in South Korean healthcare institutions. The pharmaceutical companies will be looking to improve formulation stability to prolong drug delivery and make it possible to administer dosage less frequently and for more convenience to the patient.

Targeted and smart delivery systems are growing exponentially in adoption because of the rise of precision medicine and its importance in oncology and specialty therapies. Smart delivery systems are being integrated with digital monitoring technologies for tracking dosage adherence and other factors; these are seeing accelerated use because providers are seeing improved accuracy, fewer side effects and technologically supported treatment benefits in the advanced care areas.

By End User : 

End users-Hospitals are still the main end users due to a high flow of patients for intensive care, oncology treatment and surgery which involve the use of enhanced drug delivery systems. Institutional purchases enable large-scale adoption of injectable and controlled release formulations across the network of tertiary care centers in Korea. 

Homecare usage- Strong growth in homecare use due to trend towards growing aged population, boosting the need for self administration therapy options. Clinics-- Growing use for easier delivery device usage for outpatient treatments and subsequent follow-ups. Healthcare decentralization-Trend toward more non hospital treatment environment for portable drug delivery systems

What are the Key Use Cases Driving the South Korea Drug Delivery Systems Market?

The main application for injectable biologic therapeutics is in the South Korean drug delivery systems market, driven by oncology and chronic diseases management by hospitals. The demand is for rapid therapeutic efficacy with better drug stability, in contrast to oral dosage delivery. The need for precise administration makes injectable systems indispensable in drug delivery of chemotherapy and insulin for hospitals, where the direct consequence on the treatment efficacy impacts the patient's outcome.

Home-based self administration as well as outpatient care enabled by clinics and home care services represent the extended use cases. The development of auto-injectors and wearable infusion systems supports the treatment of diabetes and rheumatoid arthritis. Hospital admissions can be avoided, while patients can adhere to therapy in a longer term as they age, enabling the continuation of treatment outside the hospitals.

Emerging applications of smart connected drug delivery systems that include digital health platforms and remote monitoring are gradually adopted for personalized therapy programs and clinical trials. Continuous feedback of the drug delivery and adaptive therapeutic administration helps to optimize the therapy efficiency over time.

Which Regions are Driving the South Korea Drug Delivery Systems Market Growth?

Seoul-Gyeonggi area leads in the South Korea Drug Delivery Systems Market due to the concentrated network of hospitals and strong presence of sophisticated tertiary care centers as well as concentration of biotech organizations. Concentration of the majority of pharmaceutical corporations headquarters along with the universities conducting research for developing new drugs/devices fosters an ongoing series of clinical trials and new device development. Proximity to regulatory agencies allows for quicker review time for sophisticated injectable and smart delivery systems, reinforcing the early adoption of biologics-based drug delivery technologies in the treatment areas of oncology and chronic diseases.

The Southeastern region (including Busan, Ulsan, Gyeongnam) has consistently been a stable part of South Korea Drug Delivery Systems Market, thanks to the presence of a robust healthcare network as well as the concentration of the majority of pharmaceutical manufacturers in the area. Rather than the rapid pace of innovation in the capital area, the growth rate in this area has been propelled more by the stable production volumes and consistent investment by institutions rather than rapidly developing R&D activities. Hospitals are bound by long-term procurement contracts to supply injectable and controlled-release systems to their patients. Industrial healthcare needs also exist in this area to serve the workforce engaged in manufacturing.

Chungcheong region with its established Osong Bio Valley appears to be the fastest growing region owing to the latest government sponsored biotech development schemes. It is characterized by new research centers and new pharmaceutical parks established after 2023 which have garnered significant domestic and global investment. Access to national clinical trial networks across regions improved, strengthening its capacity in the initial phase of drug development. The accelerated growth signifies increasing prospects for the new market participants who aim to address the decentralized innovation centers that lie outside the major metropolitan areas.

Who are the Key Players in the South Korea Drug Delivery Systems Market and How Do They Compete?

The South Korean Drug Delivery Systems market is moderately consolidated with international medical technology companies competing against pharmaceutical majors and specialty device developers. Competition is driven primarily by technology differentiation in smart delivery systems, ability to navigate regulatory requirements, and the integration of biologics-ready platforms. Established companies maintain market share through relentless product refresh strategies, while new entrants concentrate on specialized device innovation for select therapy segments.

Medtronic targets smart infusion and connected injector systems to enhance real-time dosage management in acute care settings and the key competitive advantage is its advanced device integration capabilities and broad clinical evidence base in multiple chronic disease management areas. Market expansion in Korea is driven through collaborations with large hospital networks and digital health services to build on uptake of connected delivery solutions.

Becton Dickinson leads through its advanced precision injection and safety engineered delivery devices for institutional and out-patient settings. Johnson & Johnson leads on the back of its biologics delivery compatibility and deep vertical integration with its pharma assets, most particularly within oncology. Roche leads through personalized targeted therapies requiring specific delivery systems designed to align with bespoke patient protocols. Novartis drives market leadership in slow and sustained release delivery coupled with a comprehensive range of advanced injector solutions. Gerresheimer leads by supporting manufacturing with integrated high quality packaging and primary components that facilitate a broad array of injector and smart delivery devices used by Korea pharma companies.

Company List

• Pfizer
• Novartis
• Roche
• Johnson & Johnson
• Becton Dickinson
• Baxter
• West Pharmaceutical
• Gerresheimer
• Catalent
• Ypsomed
• Insulet
• Medtronic
• Sanofi
• Takeda
• AstraZeneca

Recent Development News

In January 2026, IMARC Group reported updated projections for South Korea pharmaceutical drug delivery expansion. The report highlighted accelerated adoption of injectable and implantable delivery platforms driven by chronic disease treatment demand and biologics pipelines. Source https://www.imarcgroup.com/

In December 2025, Samsung Biologics announced acquisition of a US-based drug production facility from GSK. The move strengthens its global biologics manufacturing footprint and expands capacity to meet rising demand for advanced drug delivery and biologic production systems. Sourcehttps://www.reuters.com/

What Strategic Insights Define the Future of the South Korea Drug Delivery Systems Market?

The South Korea drug delivery systems market is restructuring into digitised, biologics-led delivery ecosystems, in which patients' self-administration, coupled with dosage precision will dictate the market's competitiveness within the next 5–7 years. Increased complex biologic pipelines, combined with the healthcare sector's consistent transition to a less-hospital-reliant outpatient / home-based care delivery system which offers consistent therapeutic intensity with reduced hospitalisation levels will be the dominant factors in this transition. 

A subtler threat to South Korea is the growing reliance on imported high precision components, and with this, increasing vulnerability to concentration and potentially unstable pricing from globally diversified suppliers. Conversely, the new opportunity within the market comes in the form of smart injectables which will incorporate artificial intelligence and link real-time monitoring of therapeutic benefit into Korea's burgeoning digital health infrastructure. South Korean market participants need to focus on establishing locally driven device manufacturing partnerships, while simultaneously concentrating on open, inter-operable delivery platforms to seamlessly integrate into hospital IT systems and remote monitoring networks

South Korea Drug Delivery Systems Market Report Segmentation

By Route

• Oral
• Injectable
• Transdermal
• Pulmonary

By Technology

• Controlled Release
• Targeted Delivery
• Smart Delivery

By End User

• Hospitals
• Clinics
• Homecare